ReviewJournal of clinical medicine2025
Artificial Intelligence in Pancreatobiliary Endoscopy: Current Advances, Opportunities, and Challenges.
Review in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in Artificial Intelligence for Gastrointestinal Endoscopy: 2026 Update.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreaticobiliary endoscopy, encompassing endoscopic ultrasound (EUS), endoscopic retrograde cholangiopancreatography (ERCP), and digital single-operator cholangioscopy (DSOC), is essential for diagnosing and managing pancreatic and biliary diseases. However, these procedures are limited by operator dependency, variable diagnostic accuracy, and technical complexity. Artificial intelligence (AI), particularly through machine learning (ML) and deep learning (DL), has emerged as a promising tool to address these challenges. Early studies show that AI can enhance lesion detection, improve differentiation of pancreatic masses, classify cystic lesions, and aid in diagnosing malignant biliary strictures. AI has also been used to predict post-ERCP pancreatitis risk and reduce radiation exposure during ERCP. Despite this promise, current AI models are largely experimental-limited by small, single-center datasets, lack of external validation, and no FDA-approved systems for these indications. Major barriers include inconsistent data acquisition, limited interoperability across hardware platforms, and integration into real-time workflows. Future progress depends on multicenter data sharing, standardized imaging protocols, interpretable AI design, and regulatory pathways for model deployment and updates. AI can be developed as a valuable partner to endoscopists, enhancing diagnostic accuracy, reducing complications, and supporting more efficient, personalized care in pancreaticobiliary endoscopy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.